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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Cost-effectiveness studies about rotavirus (RV) vaccination
programs were performed in many countries due to the severe economic burden of RV infec-
tions. This study is an economic evaluation performed to assess the potential for introducing
the RV vaccine to the Turkish National Immunization Program.
Methods: In this retrospective clinical study, the records and laboratory findings of a total of
4126 patients admitted to Turgut Ozal University Hospital, Ankara, Turkey with acute gastro-
enteritis were analyzed. A model described by Parashar et al. was used to obtain the annual
episodes of diarrhea, hospitalization and outpatients visits in Turkey. Monovalent and pentava-
lent vaccination was assumed to protect in average 85% of RV acute gastroenteritis. All costs
are expressed in 2012 United States (US) $, where US$1 equals 1.8 Turkish Liras (TL). Losses of
labor costs were not taken into consideration.
Results: The vaccination program with 85% coverage was cost effective and cost saving
compared to no vaccination. A projected birth cohort of 1.25 million children was followed un-
til 5 years of age; a routine vaccination could potentially avert 210,994 cases of diarrhea
treated in outpatient hospital facilities and 42,715 hospitalizations. The RV associated eco-
nomic burden was obtained as US$17,909 million per year (US$14.33 per birth annually) in
medical direct costs by using the national level of RV diarrhea disease burden estimates. For
monovalent and pentavalent vaccination, assuming a cost of US$31.5 and US$38 per vaccine
course, the cost of the vaccination program was estimated to be approximately US$37,878
million and US$45,475 million, respectively.istrict, Sanatoryum Street, Ardahan Road, No: 25, Department of Pediatrics, Kecioren Training and
m (O. Ozdemir).
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vaccine, routine RV vaccination could be potentially cost effective and also cost saving in
Turkey. National RV vaccinations will play a significant role in preventing RV infections.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Rotavirus (RV) is the most frequent cause of acute gastro-
enteritis (AGE) and AGE-related hospitalizations throughout
the world in children under 5 years. Rotavirus-related
gastroenteritis accounts for 10e20% of AGE and 25e55% of
AGE-related hospitalizations.1 Rotavirus diarrheas cause 111
million diarrheal episodes yearly worldwide, Due to this, 25
million outpatients and twomillion children stay in hospital.2
Annually 611,000 children die due to severe RV diarrhea and
85% of deaths occurs in developing countries.3 Incidence of
RVwhich is distinguished fromother gastroenteritis agentsby
not being related to socioeconomic conditions and hygiene
measures is the same in developed and developing countries;
while its mortality is high in developing countries; it leads to
high morbidity and economic losses in developed coun-
tries.3,4 Studies indicate that RV is one of the main causes of
gastroenteritis among children aged between 0 years and
5 years in Turkey.5 Rotavirus infectionsmaybe asymptomatic
or cause nonspecific symptoms like diarrhea, vomiting, and
fever. The frequency of RV infection increases in winter.6
Directly and indirectly, the annual cost of RV infections
to the United States is $1 billion and to the Europe is V350
million, approximately.7,8 Rotavirus infections cause eco-
nomic burden both for the families and the countries not
only due to hospitalizations but also as a result of outpa-
tient clinic admissions and loss of labor.9
There is no particular therapy for RV infection. Immuni-
zation plays a significant role for RV related morbidity and
mortality and currently two vaccines are available.10 Rotarix
(GlaksoSmithKline, Rixenrant, Belgium) and RotaTeq (Merck
Sharp&Dohme Corp., Whitehouse Station NJ, USA), two
vaccines developed against RV infections, are reported to
reduce hospital and emergency room admissions by 90%.9
These vaccines which have been used in many countries
since 2006 are currently included in routine vaccination
programs in more than 100 countries.11 Studies about cost-
effectiveness of routine vaccination continue as vaccine
prices are so high in many countries all over the world.12 It
was difficult to use the health data of one country for another
because of differences between epidemiology and health
systemofcountries.13 In this study,weaimed tocalculate the
financial burden of outpatients and hospitalized RV patients.
According to financial burden results, we estimated the cost
of RV vaccines in Turkey in which RV vaccines have not been
included in routine vaccination programs yet.
Methods
In this study, records and laboratory data of 4126 patients
younger than 5 years, who were admitted to theKoksal T, et al., Cost-effectiven
tp://dx.doi.org/10.1016/j.jmii.20Department of Pediatrics, Faculty of Medicine, Turgut Ozal
University, Ankara, Turkey with AGE between January 2005
and May 2012 were retrospectively analyzed. Rotavirus
antigens were investigated in fresh stool specimens with
the “qualitative immunochoromatographic” test (CerTest
Rotavirus kit, Biotec, Zaragoza, Spain).
This study was estimated to cover three types of hospital
(university, public, and private) costs available in Turkey
and represented an average cost of gastroenteritis due to
RV. All patients admitted to the Turgut Ozal University
Hospital, Ankara, Turkey were assumed to be admitted to a
public and a private hospital. This study was approved by
the Human Subjects’ Research Committees at the Faculty
of Medicine, Turgut Ozal University.
A resolution analytical model has been developed to
predict the effectiveness and cost effectiveness of RV in
the childhood population (< 59 months of age) with the
opportunity to focus the analysis on a risk based vaccination
program. Demographic and epidemiological inputs were
obtained from previously conducted study sources from
different regions of Turkey and international literature.
To compare the costs of the vaccination versus non-
vaccination situation and health outcomes, an incremental
cost-effectiveness ratio (ICER) was estimated as the in-
cremental cost per life year gained (LYG). Since there are
no health utility data available in Turkey, the quality of life
gained due to vaccination has not been evaluated. ICER
compares the net cost of a health intervention with the
benefit gained. The ICER was calculated for a range of
vaccine prices [United States (US)$1e40 per vaccine
course).
Bills of the in- and outpatients for RV gastroenteritis
were analyzed in detail and direct medical costs were
calculated as in the studies investigating economic burden
of RV infections at University Hospital. After the interviews
with government health officials and private hospital
managers in Ankara in 2012, estimates of costs were ob-
tained. Medical direct costs for RV-specific diarrhea were
estimated for the 2012 Turkey birth cohort. Nondirect
medical and indirect costs were not taken into account in
the model. All costs are expressed in 2012 US$, where US$1
equals 1.8 Turkish Liras (TL).
A model described by Parashar2 was used to obtain the
annual episodes of diarrhea, hospitalization and out-
patients visits in Turkey. Among the 1.25 million births
annually in Turkey (7.5 million children younger than
5 years in 2012), the annual episodes of diarrhea in Turkey
was estimated to be 13,371,800 among children younger
than 5 years, corresponding to 94,817 hospitalizations and
1,182,046 outpatient visits (Table 1).14 Rotavirus AGE
comprised 21% of the outpatient AGE cases15 and RV
gastroenteritis among all children hospitalized foress of rotavirus vaccination in Turkey, Journal of Microbiology,
16.03.005
Table 1 Estimated disease burden of rotavirus diarrhea
without a national rotavirus vaccination program in Turkey
for a 1-year birth cohort (n Z 1.25 million).a
Total diarrhea
cases (n)
RV of all
cause
diarrheas (%)
RV without
vaccination (n)
Hospitalization 94,817 53 50,253
Outpatient
visit
1,182,046 21 248,229
a The model described by Parashar et al.2
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utility data available in Turkey. Therefore, the data of
deaths related with RV has not been evaluated and not
taken into account in the model.
A two-dose vaccination program for monovalent and
three-dose vaccination program for pentavalent RV vac-
cine total costs were calculated based on the number of
vaccines required to vaccinate 1.25 million infants annu-
ally. The efficacy of the monovalent and pentavalent RV
vaccines are 84%/90% for reduction in hospitalizations and
70%/85% for reduction in outpatients visits, respectively.16
Vaccine coverage was estimated based on reports for
other vaccines given at the same age (pneumococcal
conjugate vaccine) in Turkey (81.6e89.5%).17 We assumed
the mean coverage rate of both vaccines was 85% in the
national immunization program. Vaccination costs
included the vaccine price and procedure fees for vaccine
administration. To take RV vaccines into the National
Vaccination Schedule a considerable cost reduction should
be carried out by the Ministry of Health. Based on previ-
ous experience of the Ministry of Health with other vac-
cines (Prevenar-7 (Pfizer, Philadelphia, USA) and
Prevenar-13 (Pfizer, Philadelphia, USA)) which were
recently added into the Turkish National Vaccination
Schedule, the cost of the RV vaccine course would be 1/
5e1/8 of the market prices (In Turkey 2012, the market
prices were US$157.8 per course for monovalent and
US$190 per course for pentavalent vaccines). We calcu-
lated the estimated maximum price (1/5 of the market
price) that would be in a national vaccination schedule for
the RV vaccine. According to these data we assumed theTable 2 Estimated mean (standard deviation) values for dire
children treatedb in university, public, and private hospitals.
H
University Publ
Hospitalization costs (US$) 173.06  106.49 123.
Outpatient costs (US$)c 27 21.6
a Costs expressed in 2012 US$ (US$1 Z 1.8 TL).
b Mean duration of hospital stay was calculated as 3.9  2.4 days.
c Outpatient costs ($) in university and public hospitals were calcula
tariff (only 1 price).
d Outpatient cost in a private hospital was the calculated package
TL Z Turkish Liras; US Z United States.
Please cite this article in press as: Koksal T, et al., Cost-effectiven
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were US$31.5 and US$38, respectively.
Economic modeling methods outlined in the WHO
generic protocol to estimate health care costs of RV-
specific diarrhea and cost-effectiveness of RV vaccination
were used.18
A model was used that incorporates information on dis-
ease burden, vaccine coverage, and vaccine effectiveness
to obtain the cost effectiveness of a routine vaccination
program. Vaccination costs included the cost of adminis-
tration, the price of the vaccine, and expected losses from
unused vaccines. The estimated cost of vaccine adminis-
tration was US$1 per vaccine course. A national RV immu-
nization program would cost:
[(1.25 million children  coverage %)  US$ (1e40) þ (1.25
million children  coverage %)  administration cost)]. (1)
Demographic data on the Turkish population was based
on the national statistics data from 2012. The national gross
domestic product (GDP) per capita in Turkey in 2012 was
18,957 TL (US$10,504).19Results
Of 4126 patients included in the study, 1782 (43.2%) are
girls and 2344 (56.8%) are boys. Rotavirus was positive in
1261 patients (30.6%). Mean age of RV positive patients
was 31.1  22.6 months. Two hundred and eighteen RV
positive patients were followed up in the hospital, the
others were outpatients and mean duration of hospital stay
was 3.9  2.4 days.
Economic burden of rotavirus diarrhea
Economical data was combined with RV-positive patients
having acute diarrhea. Patient hospital expenditures were
computed using the official hospital invoices. All patients
admitted to the university hospital were assumed to be
admitted to a public and a private hospital (Table 2). Total
direct medical costs of the university hospital were 1.4
times higher than the public hospital and private hospital
costs were two times higher than the university hospital.
The average direct medical costs (hospitalization,ct medical costsa associated with rotavirus diarrhea among
ospital Average
ic Private
89  76.24 383.99  236.30 226.98  139.68
30  15d 26.2  5
ted based on fiscal control formal health institution package price
price tariff (only 1 price) þ the mean cost of extra charge.
ess of rotavirus vaccination in Turkey, Journal of Microbiology,
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facilities (university, public, and private hospital) were
simulated to the model described by Parashar et al2 to
obtain the economic burden of RV specific diarrhea in
Turkey. The RV associated economic burden was found to
be US$17,909 million per year (US$14.33 per birth annually)
in direct medical costs by using the national level of RV
diarrhea disease burden estimates (Table 3).Table 3 Economic burden of rotavirus-specific diarrhea in
Turkey.
Total mean costa in 1000s
(95% confidence interval)
Annual
average
total cost
per childb
Hospitalization Outpatient
visits
Total
cost
Medical
direct
cost ($)
11,406
(4387e18,425)
6503
(5262e
7746)
17,909
(9649e
26,171)
14.33
(7.72e20.94)
a Costs expressed in 2012 US$ (US$1 Z 1.8 TL).
b Based on a 1-year birth cohort (1.25 million).
TL Z Turkish Liras; US Z United States.
Table 4 Percentage reduction due to a national mono-
valent and pentavalent rotavirus vaccination program.
Reduction due
to vaccination
(%)
Prevented by
vaccination (n)
RV with
vaccination
(n)
Hospitalization
Monovalent 84 42,212 8041
Pentavalent 90 45,211 5042
Mean coverage
(estimated)
85 42,715 7538
Outpatient visit
Monovalent 70 173,760 74,469
Pentavalent 85 211,054 37,174
Mean coverage
(estimated)
85 210,994 37,235
Table 5 Economic benefits of rotavirus-specific diarrhea preve
Medical direct
cost (US$)
Total mean cost
(95% confidence
Hospitalization Outpatient
Monovalent 9581 (3685e15,477) 4552 (3683e
Pentavalent 10,261 (3946e16,577) 5529 (4474e
Mean coverage
estimated (85%)
9695 (3728e15,661) 5528 (4472e
a Costs expressed in 2012 US$ (US$1 Z 1.8 TL).
b Based on a 1-year birth cohort (1.25 million).
TL Z Turkish Liras; US Z United States.
Please cite this article in press as: Koksal T, et al., Cost-effectiven
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Introduction of monovalent RV vaccines into the Turkish
National Immunization program could prevent w42,212
hospitalizations and 173,760 outpatient visits and 45,211
hospitalizations and 211,054 outpatient visits for the
pentavalent vaccine. If the mean coverage rate of both
vaccines was estimated to be 85%, prevention was
w42,715 hospitalizations and 210,994 outpatient visit
(Table 4). Multiplying our cost estimates by the number of
healthcare visits averted, introduction of monovalent RV
vaccines into the Turkish National Immunization program
could save US$14,133 million per year (US$11.30 per birth
annually), US$15,790 million per year (US$12,632 per birth
annually) for the pentavalent vaccine and US$15,223
million per year (US$12.17 per birth annually) for
estimated mean coverage rate (85%) of both vaccines
(Table 5).
Cost of RV vaccination program
At a cost per child (US$1e40 per vaccine course), with a
vaccine administration cost of US$1 per child and a vaccine
coverage rate of 85%, we assumed the cost of the mono-
valent and pentavalent RV vaccine course were US$31.5
and US$38, respectively. The cost of a national RV immu-
nization program for monovalent and pentavalent vaccine:
[(1.25 million children  coverage 85%)  US$ (31.5/
38) þ (1.25 million children  coverage 85%)  US$1)]Z for
monovalent vaccine Z US$34,531,250 and for pentavalent
vaccine Z US$41,437,500 (2)Incremental cost and cost-effectiveness ratio
The incremental costs for monovalent and pentavalent
vaccines were estimated at US$3776 and US$2119 million,
retrospectively. The cost-effectiveness ratio for the
monovalent vaccine was ICER Z US$3667/LYG and for
pentavalent vaccine ICER Z US$4615/LYG. Both of them
were lower than the national GDP per capita in Turkey
(US$10,504 per capita in 2012; Table 6). Therefore, the
national vaccination program can be considered as cost-
effective if the cost of a vaccination course would be 1/5nted by vaccination in Turkey.
a in 1000s
interval)
Annual average total
cost per childb
Total cost
5421) 14,133 (7368e20,898) 11.30 (5.89e16.72)
6584) 15,790 (8420e23,161) 12.632 (6.74e18.53)
6584) 15,223 (8200e22,245) 12.17 (656e1779)
ess of rotavirus vaccination in Turkey, Journal of Microbiology,
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Table 6 Base case results of cost effectiveness analysis of
vaccination (the mean coverage rate of both vaccines is
85%) (TUIK 2012: GDP per capita Z US$10,504).
Number of life year gained (LYG)
For monovalent vaccine 4.356 (4.214e4.498)
For pentavalent vaccine 4.778 (4.257e5.319)
Vaccination costsa
For monovalent vaccine
(US$31.5 per course)
34,531,250
For pentavalent vaccine
(US$38 per course)
41,437,500
Cost effectiveness analysisb
ICER (US$/LYG)
For monovalent vaccine US$3667/LYG (1887e5447)
For pentavalent vaccine US$4615/LYG (2342e6888)
a Based on a 1-year birth cohort (1.25 million).
b ICERZ (total cost of vaccination for birth cohort - total cost
of no vaccination)/LYG.
GDP Z gross domestic product; ICER Z incremental cost-
effectiveness ratio; TUIK Z Turkish Statistical Institute; TL
Turkish Liras; US Z United States.
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pentavalent (US$38) vaccines.
Discussion
This economic evaluation provides information for decision
making for the introduction of the RV vaccine into the
Turkish National Immunization Program. Although the re-
sults of the costs of RV disease that were avoided by
vaccination were less than the cost of a vaccination pro-
gram, both RV vaccination strategies were cost effective
and cost saving because ICER’s for both vaccines were
lower than the national GDP per capita in Turkey
(US$10,504 per capita in 2012).19
This study was estimated to cover three types of hospital
(university, public, and private) costs available in Turkey
and represented an average cost of gastroenteritis due to
RV. All patients admitted to the university hospital were
assumed to be admitted to a public and a private hospital.
The average total direct cost for the three facilities (uni-
versity, public, and private hospital) was
US$226.98  139.68. Expenditures of diagnosis and treat-
ment accounted forw67% of total direct costs. Total direct
medical cost per patient was US$151, another study per-
formed in the training and research hospital found that 65%
of this cost was related to treatment and diagnosis ex-
penditures.20 The differences arise as the study was per-
formed only at a public hospital. In a study conducted in
Mexico, the total direct medical cost per patient was
US$211 and diagnostic procedures and medications con-
sisted of 92% of this cost.21
In our study, vaccination can effectively reduce the
burden and healthcare costs of RV. Total direct medical
costs were US$17,909 million (US$14.33 per birth annually)
and US$15,223 million (US$12.17 per birth annually) could
be prevented if the RV vaccine is included in the vacci-
nation program. In comparison with RV AGE costs inPlease cite this article in press as: Koksal T, et al., Cost-effectiven
Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.20several studies, the costs of illness in our study have
turned out to be less. With regards to the rules and reg-
ulations in effect in Turkey, the public payer is responsible
for a large amount of population-based health costs, and
the public payer cost is usually cheaper than private hos-
pitals in Turkey. If the costs of RV infection are retrieved
from a university hospital, costs are expected to be higher
than in a public hospital due to relatively higher prices,
the availability of a greater number of procedures, and
more advanced technology. The costs from a private hos-
pital are expected to be higher than in a university and
public hospital because of the extra charges. It is known
that RV cases are seen less and hospitalizations are less in
developed countries however, the economic burden of the
disease is greater than in Turkey due to the high expen-
diture of health services.22 In a study from the United
States of America, the mean direct cost was US$4565.23
The results in a study investigating the effectiveness of
RV vaccine in Canada were similar to ours. In public health
perspective, cost of vaccination was found to be greater
than not vaccinating (US$69) both for RotaTeq (Merck
Sharp&Dohme Corp., Whitehouse Station NJ, USA) (US$207
for one course) and Rotarix (GlaxoSmithKline, Rixenrant,
Belgium) (US$199 for one course). However, the 5-year
economic burden of RV infections is much more than
US$125 million.24
In our study the cost effectiveness ratio was US$3667/
LYG for monovalent vaccine and US$4615/LYG for penta-
valent vaccine, which is largely lower than the national GDP
per capita in Turkey (US$10,504 per capita in 2012) and
therefore cost-effective. A national vaccination program
can be considered as cost-effective if the costs of the
vaccination course would be  1/5 of the marketing prices
for monovalent (US$31.5) and pentavalent (US$38) vac-
cines. This is a desired result but not appropriate for Turkey
yet. The results of our analyses are similar with other an-
alyses performed on RV monovalent or pentavalent vac-
cines, which demonstrated that an RV vaccination is likely
to be cost effective.16,25 RV vaccinations were previously
reported to be cost-effective across various European
countries.16 A cost-effectiveness analysis for RV vaccination
in England and Wales showed that routine vaccination of all
children appeared to be cost effective.1 In the study per-
formed in Thailand, generalization of the RV vaccine was
reported to be beneficial both for the disease and economy
however the price of the vaccine should be less than
US$10.26
At present, Turkey has not undertaken universal immu-
nization of infants with RV, although it is considering the
implementation of such a program. The future effect of an
RV vaccination program in Turkey will depend on the vac-
cine coverage rate and serotype and their clinical
importance.
In our study, considerable healthcare and societal
costs result from the estimated 50,253 hospitalizations
and 248,229 outpatient visits to hospital facilities per
year in children younger than 5 years attributable to RV.
In a study from Vietnam, RV vaccines reduce outpatient
clinic admissions, hospitalizations, and deaths by > 67%
and the vaccine was found to be effective in terms
of public health.27 Similar results have been found in a
study from Bolivia. Rotavirus vaccination was seeness of rotavirus vaccination in Turkey, Journal of Microbiology,
16.03.005
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and total direct expenses by 60%. The price of the vac-
cine was reported to be US$9 for each dose in order to be
cost-effective.28
A limitation of our analysis is that it was assumed that
there was no loss of labor and there was the same vaccine
efficacy for all ages, including the first 2 months when full
immunization would not yet have been achieved. The in-
direct medical and nonmedical costs for the RV AGEs were
not included in this study. They may even exceed the direct
medical costs of RV AGE and may add extra benefits to cost
effectiveness of the RV vaccination.
In recent studies, the RV vaccine was shown to protect
not only vaccinated babies but also nonvaccinated babies
and older children, in other words provide “herd immu-
nity”.29 These studies support the recommendation of WHO
that the RV vaccine should be added to the national
vaccination program in all countries worldwide.
Rotavirus disease among Turkish children causes signifi-
cant morbidity and mortality and important costs to the
Turkish healthcare system. Vaccination can effectively
decrease this burden and healthcare costs. If the available
prices are approximately  US$31.5 for monovalent and 
US$38 for pentavalent per course; the cost per LYG for both
vaccines are estimated to be lower than one GDP per capita
in Turkey. Vaccination of children with RV is not publicly
funded in Turkey. As a result, the RV vaccine coverage rate
in Turkey has been minimal and its’ increase should
improve public health. More cost-effectiveness studies are
needed in order to include RV vaccines into routine vacci-
nation programs. Informing families and increasing vacci-
nation rates, reducing high prices will play an important
role in the prevention of RV infections until the vaccine is
included in the national vaccination program. Considering
all costs (direct medical, indirect medical, and nonmed-
ical), a RV vaccination program in Turkey will be cost saving
and cost-effective.Conflicts of interest
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